自适应肿瘤追踪对比ITV概念在胰腺癌SBRT中的剂量学优势
该治疗计划研究为12例既往治疗的胰腺癌患者分别设计ITV概念与肿瘤追踪的VMAT计划(5×5 Gy),并进行4D剂量计算。肿瘤运动范围为1.3至11.2 mm,追踪使PTV最大缩小39.2%,在3D和4D剂量计算中均显著改善肿瘤覆盖(p<0.05)并降低十二指肠、胃和肝脏平均剂量(p<0.05)。
要点
- 肿瘤追踪较ITV概念使PTV最大缩小39.2%。
- 追踪在3D和4D剂量计算中均显著改善肿瘤覆盖(p<0.05)。
- 追踪显著降低十二指肠、胃和肝脏平均剂量(p<0.05)。
核心结论
- 采用自适应肿瘤追踪管理呼吸运动可显著缩小PTV并改善危及器官剂量保护,其剂量学获益具有器官和患者特异性。
研究设计与样本
- 治疗计划研究,对12例既往治疗的胰腺癌患者分别创建ITV概念和肿瘤追踪的VMAT计划(5×5 Gy),并在4DCT扫描上进行4D剂量计算。
主要发现
- 肿瘤运动范围为1.3至11.2 mm。
- 追踪使PTV最大缩小39.2%,在3D和4D剂量计算中均显著改善肿瘤覆盖(p<0.05,配对Wilcoxon符号秩检验)。
- 追踪在3D和4D剂量计算中均显著降低十二指肠、胃和肝脏的平均剂量(p<0.05)。
临床怎么用
- 对于呼吸运动明显的胰腺癌SBRT,可考虑采用自适应肿瘤追踪以缩小PTV并改善危及器官保护。
局限性
- 剂量学获益具有器官和患者特异性,需个体化评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radiotherapy for pancreatic cancer has two major challenges: (I) the tumor is adjacent to several critical organs and, (II) the mobility of both, the tumor and its surrounding organs at risk (OARs). A treatment planning study simulating stereotactic body radiation therapy (SBRT) for pancreatic tumors with both the internal target volume (ITV) concept and the tumor tracking approach was performed. The two respiratory motion-management techniques were compared in terms of doses to the target volume and organs at risk. METHODS AND MATERIALS: Two volumetric-modulated arc therapy (VMAT) treatment plans (5 × 5 Gy) were created for each of the 12 previously treated pancreatic cancer patients, one using the ITV concept and one the tumor tracking approach. To better evaluate the overall dose delivered to the moving tumor volume, 4D dose calculations were performed on four-dimensional computed tomography (4DCT) scans. The resulting planning target volume (PTV) size for each technique was analyzed. Target and OAR dose parameters were reported and analyzed for both 3D and 4D dose calculation. RESULTS: Tumor motion ranged from 1.3 to 11.2 mm. Tracking led to a reduction of PTV size (max. 39.2%) accompanied with significant better tumor coverage (p<0.05, paired Wilcoxon signed rank test) both in 3D and 4D dose calculations and improved organ at risk sparing. Especially for duodenum, stomach and liver, the mean dose was significantly reduced (p<0.05) with tracking for 3D and 4D dose calculations. CONCLUSIONS: By using an adaptive tumor tracking approach for respiratory-induced pancreatic motion management, a significant reduction in PTV size can be achieved, which subsequently facilitates treatment planning, and improves organ dose sparing. The dosimetric benefit of tumor tracking is organ and patient-specific.
引用
- Karava K, Ehrbar S, Riesterer O, et al. Potential dosimetric benefits of adaptive tumor tracking over the internal target volume concept for stereotactic body radiation therapy of pancreatic cancer. Radiat Oncol. 2017. PMID: 29121945. doi:10.1186/s13014-017-0906-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。